Unicancer — Sponsor Intelligence | 63 EU Trials

Filter these 63 trials by condition, phase, country and more.

Open in Search →

63 Registered trials

31 Recruiting

27 Completed trials

12 Countries active

91 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 25 Phase II/III: 1 Phase II: 36 Other: 1

Oversight events:

1 temporary halt 1 corrective measure across 2 trials

View oversight register →

100%

27 of 27 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Prostate cancer 3 Triple negative breast cancer 3 Breast cancer 2 Head and neck cancer 2 Bladder cancer 2 Ewing´s sarcoma metastatic 1 HER2 positive colorectal cancer 1 Non-small cell lung cancer metastatic 1 Prostate cancer metastatic 1 Soft tissue sarcoma 1 Biliary cancer metastatic 1 Breast cancer stage I 1

Top IMPs

DURVALUMAB 7 DAROLUTAMIDE 4 PEMBROLIZUMAB 4 ATEZOLIZUMAB 2 BINIMETINIB 2 CAPECITABINE 2 DOXORUBICIN HYDROCHLORIDE 2 ENCORAFENIB 2 FULVESTRANT 2 IVONESCIMAB 2 TRASTUZUMAB 2 TRIFLURIDINE, TIPIRACIL 2

All trials

63 total

A Phase III study evaluating the efficacy of atezoliumab administration in addition to BCG (Bacillus Calmette-Guerin) for 1 year in patient… Pending

2024-517621-54-00 Phase III 3 countries ATEZOLIZUMAB
Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Pending

2024-519655-28-00 Phase III 7 countries
Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test Pending

2025-521045-24-00 Phase III 2 countries CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN
Study evaluating two treatment strategies for rectal cancer in patients ≥75 years old Pending

2025-521619-37-00 Phase III 1 country
Testing two different drugs (sacituzumab-govitecan and trastuzumab-deruxtecan) combinations prescribed in an alterning pattern to patients w… Pending

2025-521909-40-00 Phase II 1 country
Clinical trial evaluating the biological activity of a new drug identified as prifetrastat (PF-07248144), combined with fulvestrant for the … Pending

2025-521982-29-00 Phase II 1 country 2-METHOXY-N-{4-METHOXY-6-[(1H-PYRAZOL-1-YL)METHYL]-1,2-BENZOXAZOL-3-YL}BENZENE-1…
METAREM / META-1 - METAREM :Immunotherapy Master Trial for Advanced Cancers / META-1: Immunotherapy without chemotherapy for advanced lung c… Pending

2025-522655-26-00 Phase II 1 country CEMIPLIMAB; PEMBROLIZUMAB
Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending

2025-523683-20-00 Phase II 1 country
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Phase III 5 countries
NEOREM/NEO-1 - NEOREM: Neo-adjuvant Immunotherapy Master Trial for Localized Cancers / NEO-1: Neo-adjuvant immunotherapy in patients with l… Recruiting

2025-522127-95-00 Phase II 1 country IPILIMUMAB; NIVOLUMAB
Clinical trial evaluating the activity of zanidatamab for the treatment of patients with solid tumors with an alteration of the HER2 gene Recruiting

2025-522169-31-00 Phase II 1 country ZANIDATAMAB
Testing ivonescimab in combination with standard chemotherapy in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients Recruiting

2025-520694-39-00 Phase II 1 country IVONESCIMAB
Durvalumab and tremelimumab with or without Hepatic Arterial Infusion of gemcitabine and oxaliplatin in hepatocellular carcinoma patients. Recruiting

2024-514912-28-00 Phase II/III 1 country DURVALUMAB; TREMELIMUMAB
Testing ivonescimab versus FOLFOX in advanced biliary tract cancer patients Recruiting

2024-515875-36-00 Phase II 1 country IVONESCIMAB
Detection of tumour DNA in the blood of patients receiving standard therapy for hormone receptor-positive (HR+) HER2 low expression (HER2 lo… Recruiting

2024-515349-41-00 Phase II 1 country TRASTUZUMAB DERUXTECAN
Personalizing the use of pembrolizumab for patients who have a strong response in early triple negative breast cancer Recruiting

2024-515787-31-00 Phase III 2 countries
Clinical trial evaluating the efficacy of pemigatinib for the treatment of patients with solid tumours with an alteration of the gene FGFR Recruiting

2024-512729-10-00 Phase II 1 country PEMIGATINIB
Capecitabine plus pembrolizumab in patients with triple negative breast cancer after chemoimmunotherapy and surgery Recruiting

2023-505291-30-01 Phase II 1 country
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-509787-15-00 Phase III 2 countries DAROLUTAMIDE
Dose individualization of chemotherapy in patients with gastrointestinal cancers lacking a specific liver enzyme Recruiting

2023-509963-25-00 Phase II 1 country
Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting

2023-509811-98-00 Phase II 1 country
Interest of post-operative chemotherapy in patients with localized uterine leiomyosarcoma suspected to have a high-risk of relapse based on … Recruiting

2023-506350-21-00 Phase II 1 country DOXORUBICIN HYDROCHLORIDE; TRABECTEDIN
Safety of Trifluridine/tipiracil in patients with dihydropyrimidine dehydrogenase deficiency diagnosed with metastatic colorectal or gastroe… Recruiting

2023-508724-35-00 Phase II 1 country TRIFLURIDINE, TIPIRACIL; TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE
Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-neg… Recruiting

2023-504620-26-00 Phase II 2 countries PEMBROLIZUMAB

Showing 1–24 of 63 trials

← All sponsors A–Z